PEPTIDE CORTEXThe library
← The library

Tirzepatide

Zepbound/MounjaroMetabolic/Weight
Evidence grade
AFDA-approved Rx (labeled use)
Cardiovascular · 0–5 · separate axis
5
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss
MechanismDual GIP/GLP-1 agonist: appetite reduction + improved glycemic control
EffectsLess hunger, slower digestion, better blood sugar; often improves BP and overall CV risk
Dosing2.5 mg weekly start → 5 mg; may increase by 2.5 mg q≥4 weeks; max 15 mg weekly
Bottom lineStrongest data when used for its labeled indication under clinician guidance.
Protocols · as published3 sourced
FDA labelZepbound (label revised 02/2026)
RouteSubcutaneous injection
FrequencyOnce weekly
Starting2.5 mg once weekly for 4 weeks (initiation; not approved as a maintenance dosage)
EscalationIncrease in 2.5 mg increments after at least 4 weeks on the current dose (5, 7.5, 10, 12.5, 15 mg)
TargetWeight reduction and long-term maintenance: 5 mg, 10 mg or 15 mg once weekly. Obstructive sleep apnea: 10 mg or 15 mg once weekly.
Maximum15 mg once weekly for all indications

If a maintenance dosage is not tolerated, the label says to consider a lower maintenance dosage. With oral contraceptives, use a barrier method for 4 weeks after starting and after each escalation.

FDA labelMounjaro (type 2 diabetes)
RouteSubcutaneous injection
FrequencyOnce weekly
Starting2.5 mg once weekly
Escalation5 mg after 4 weeks; if more glycemic control is needed, increase in 2.5 mg steps after at least 4 weeks on the current dose
TargetPer glycemic response
Maximum15 mg once weekly

Taken from search-result extracts of the label, not a line-by-line read of the PDF.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous injection
FrequencyOnce weekly
Starting2.5 mg weekly for 4 weeks
Escalation2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, with at least 4 weeks between steps
Target5, 10 or 15 mg; the page says "most users stabilize at intermediate doses without reaching maximum"
CycleAt least 24 weeks to climb the full ladder, then ongoing
Batches on file8
30 mgJA-68244 · 2025-0699.61%
15 mgJA-58539 · 2025-0399.75%
30 mgJA-63068 · 2025-0499.30%
60 mgJA-63069 · 2025-0499.44%
60 mgJA-70683 · 2025-0799.39%
10 mgJA-205037 · undatedno purity figure
30 mgJA-205038 · undatedno purity figure
40 mgJA-205039 · undatedno purity figure
Read with10
Cautions & interactions

GI side effects; pancreatitis risk; gallbladder disease; thyroid C-cell tumor warning; hypoglycemia with insulin/sulfonylureas

Caution with insulin/sulfonylureas (hypoglycemia risk); delays gastric emptying may affect absorption of oral meds; monitor for dehydration if on diuretics.

CV 5 of 5 — Strong human outcomes data via diabetes/obesity trials; improves multiple CV risk factors (weight, glucose, BP).